Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6172| Title: | Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study | Authors: | Sundar Jagannath Thierry Facon Ashraf Z. Badros Moshe Levy Philippe Moreau Sosana Delimpasi Maryana Simonova Ivan Spicka Iryna Kriachok Maria Gavriatopoulou Halyna Pylypenko Holger W Auner Xavier Leleu Vadim Doronin Ganna Usenko Roman Hajek Reuben Benjamin Tuphan Kanti Dolai Dinesh Kumar Sinha Chris P. Venner, Mamta Garg Mercedes Gironella Mesa Artur Jurczyszyn Tadeusz Robak Monica Galli Wallington-Gates, Craig Thomas Atanas Radinoff Galina Salogub Don Stevens Supratik Basu Anna Marina Liberati Hang Quach Veselina S Goranova Marinova Jelena Sreten Bila Eirini Katodritou Andrew DeCastro Yi Chai Dane R. Van Domelen Moran Mishal Ohad S. Bentur Jatin Shah Sharon Shacham Michael G. Kauffman Sebastian Grosicki Paul G. Richardson |
Issue Date: | 2021 | Publisher: | American Society of Hematology | Source: | Blood, 2021, 138 (Supplement 1): 3793. | Journal Title: | Blood | Abstract: | Introduction: Treatment of multiple myeloma (MM) has greatly improved over the last two decades. However, most pts will relapse and develop refractory disease. Most anti-cancer regimens require dose modifications (interruption, reduction, or discontinuation) during the treatment course in order to optimize the therapeutic window; appropriate modifications improve tolerability while maintaining anti-cancer activity. | DOI: | 10.1182/blood-2021-146003 | metadata.dc.rights.holder: | Craig Wallington-Gates | Type: | Article |
| Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.